BioNTech CEO confident Covid-19 vaccine will work on new UK variant

Ugur Sahin, CEO of Biontech, gestures during an interview in Mainz, Germany, Wednesday, Nov. 27, 2019. (Andreas Arnold/dpa via AP)
German pharmaceutical company BioNTech is confident that its coronavirus vaccine works against the new UK variant, but further studies are need to be completely sure, its chief executive said Tuesday.

 
The variant, detected mainly in London and the southeast of England in recent weeks, has sparked concern worldwide because of signs that it may spread more easily. While there is no indication it causes more serious illness, numerous countries in Europe and beyond have restricted travel from the UK as a result.

 
“We don’t know at the moment if our vaccine is also able to provide protection against this new variant,” Ugur Sahin told a news conference the day after the vaccine was approved for use in the European Union. “But scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variants.”

 
Sahin said that the proteins on the UK variant are 99% the same as on the prevailing strains, and therefore BioNTech has “scientific confidence” that its vaccine will be effective.

 
“But we will know it only if the experiment is done and we will need about two weeks from now to get the data,” he said. “The likelihood that our vaccine works ... is relatively high."

 
Should the vaccine need to be adjusted for the new variant the company could do so in about 6 weeks, said Ugur, though regulators might have to approve the changes before the shots can be used.

 
BioNTech’s vaccine, developed together with U.S. pharmaceutical company Pfizer, is authorized for use in more than 45 countries including Britain, the United States and the EU.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel